Related Experiment Video
Updated: Jan 17, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Guselkumab effectiveness in real-world settings: observations from an Italian multicentre study.
Andrea Becciolini1, Antonio Marchesoni2, Simone Parisi3
1Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
Guselkumab demonstrates sustained effectiveness in psoriatic arthritis (PsA) patients in real-world settings, with over two-thirds remaining on therapy after two years. Factors like enthesitis and axial involvement influence treatment persistence.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition.
- Guselkumab, a biologic disease-modifying antirheumatic drug (bDMARD), shows efficacy in randomized controlled trials.
- Real-world data on guselkumab effectiveness in PsA is limited.
Purpose of the Study:
- To evaluate the real-world effectiveness of guselkumab in PsA patients.
- To identify factors influencing clinical outcomes and treatment persistence with guselkumab.
Main Methods:
- Retrospective, observational, multicentre study of 278 PsA patients across 26 Italian rheumatology centers.
- Data collected on patient history, PsA subtype, and disease activity.
- Kaplan-Meier curves for retention rates; Cox proportional hazards analysis for factors influencing persistence.
Main Results:
- Retention rates at 6, 12, and 24 months were 90.4%, 80.0%, and 67.8%, respectively.
- Primary inefficacy (48%) and secondary inefficacy (41%) were main discontinuation reasons.
- Treatment persistence was influenced by sex, smoking, concurrent csDMARDs, corticosteroid use, year of prescription, and axial/enthesitic involvement.
Conclusions:
- Guselkumab shows sustained effectiveness and favorable retention rates in real-world PsA management.
- Adverse events led to <10% of discontinuations.
- Effectiveness is higher in patients with enthesitic/axial PsA, suggesting guselkumab as an optimal monotherapy choice for these subgroups.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Bioavailability Study Design: Healthy Subjects Versus Patients
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.